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Abstract
Burkitt s´ lymphoma (BL) is a neoplasm which, despite its very aggressive behaviour is potentially curable. It typi-
cally affects the paediatric population. BL belongs to the non-Hodgkin lymphomas group, and is the first human 
tumour undoubtedly related to a viral origin (Epstein-Barr virus). Two main clinical subtypes are recognized: 
endemic or African type, and sporadic type; HIV associated BL constitutes a third type. Although common in 
endemic BL, maxillary involvement is rare in sporadic cases. This, together with the clinical lack of specificity as-
sociated to this location, makes diagnosis difficult. New chemotherapeutic protocols achieve a high survival rate. 
Most important prognostic factors are location and tumour stage.  We report a paediatric case of BL presenting in 
the maxilla, with a review and a description of the characteristics of the disease.  
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Introduction
BL is an aggressive tumour typically, but not exclu-
sively, affecting children. It belongs to the undifferenti-
ated non-Hodgkin lymphomas and it is an extra nodal 
tumour composed of a monoclonal proliferation of un-
differentiated B cells (1). BL is related to Epstein-Barr 
virus (EBV) (1-3). Three clinical subtypes are admitted: 
African or endemic, American or sporadic, and HIV as-
sociated subtypes (4). The Irish surgeon Denis Burkitt 
first reported in 1958 its high prevalence in the maxillae 
of Central-African children (5-7); its presence in the rest 
of the world was later observed. BL represents 3-5% of 
all lymphomas. It usually affects children, representing 
up to 40% of all children’s head and neck lymphomas 
(3). Endemic BL affects African communities in the 
central and sub-Saharan areas, where its incidence is 
5-15 cases per 100000 children. The incidence of spo-
radic subtype, in the rest of the world is 1-3 cases per 
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100000 children (2). HIV associated subtype represents 
35-40% of non-Hodgkin lymphomas appearing in posi-
tive HIV population. Although silent in early stages, BL 
is a rapidly growing and expanding tumour. Signs and 
symptoms depend on primary location of the tumour 
and its degree of spread (3). Endemic subtype mainly 
affects maxillary bones (5,6), but secondarily other fa-
cial bones and abdominal organs may become affected. 
Sporadic subtype usually presents as an abdominal or 
pelvic mass, and Waldeyer s´ ring is commonly affected 
(3).
From 1970 on, the development of a combined protocol 
of chemotherapeutic agents and the use of new antibiot-
ics have determined an improvement in the prognosis of 
BL affected patients. Anatomical sites and early treat-
ment are today considered main prognostic factors.
Case Report
A male white 5 year-old child from Córdoba province 
(Spain) was admitted to the Oral and Maxillofacial Sur-
gery Unit in July 1993 because of a one month painful 
hard swelling in his right upper bucal sulcus accompa-
nied by a non adherent right submandibular adenopathy. 
No diplopia, anosmia or teeth mobility were detected. 
Among his past history, rickets could be elicited. Or-
thopantomogram showed upper right maxillary bone 
destructuration (Fig. 1). Waters view revealed destruc-
tion of the right zygomaticomaxillary buttress and max-
illary sinus opacification. Computed tomography (CT) 
showed a 5x5 cm soft density mass affecting the right 
maxillary sinus, orbital floor, and lateral nasal wall, that 
laterally displaced the zygomatic arch (Fig. 2). No tu-
mour was detected at any other location. A biopsy was 
taken and the result was Burkitt s´ lymphoma. Micro-
scopic description reported a diffuse “starry sky” pat-
tern. Phenotype was positive for CD20 and negative 
for CD2. The tumour showed a high proliferative index 
(MIBI) and a marked expression of p53 and Rb genes. 
Neither in situ hybridation nor immunohystochemical 
techniques showed evidence of EBV.  Once haematolo-
gy unit had staged the disease, chemotherapy composed 
of ciclophosphamide, vincristine, metrotrexate, and 
prednisone (COMP), with intrathecal metrotrexate was 
instituted. Later on, loco regional radiotherapy with a 
total dose of 26 Gy with Co-60 photons on the right 
maxillary sinus, orbital floor, nasal cavity, hard palate 
and first lymph node echelon was applied.
Twelve years after diagnosis, clinical and radiographic 
follow up confirms a complete remission of the disease. 
In this moment, the patient is under orthodontic treat-
ment and shows right maxillomandibular hypoplasia 
with moderate external facial asymmetry. Orthopanto-
mogran shows lack of development of right maxillary 
teeth, probably related to chemo and radiotherapeutic 
treatment received at the age of five years (Fig. 3).
Fig. 1. Orthopantomogram at presentation.
Fig. 2. CT showing the tumour in right maxillary sinus.
Fig. 3. Orthopantomogram at ten years of age, showing a retained 
upper right canine and some other dental alterations caused by radio-
therapy and chemotherapy received at the age of 5 years.
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Discussion
Paediatric non-Hodgkin lymphomas evolve more rap-
idly than those in adulthood (3). There exist clinico-
pathological differences among the different subtypes 
of BL (Table 1). Mean age of presentation in the en-
demic subtype is 7 years of age, while that in sporadic 
subtypes is 14 years of age (5). Maxillary involvement 
in the endemic subtype is age-dependant; 75% of af-
fected children under 5 years of age develop maxillary 
tumour whereas only 25% of those over 14 years of age 
do. This fact may suggest a stimulating effect induced 
by growth factors involved in child s´ dental and osseous 
development (2). Upper jaw is twice affected as lower 
jaw and several quadrants may be simultaneously af-
fected (2). BL represents 45% of all maxillary tumours 
among children under 14 years of age in Sub-Saharan 
Africa (1). Males are affected three times more often 
than girls (8). In sporadic cases of BL bone maxillary 
tumours appear only in 12-20% , and there appears to 
be no geographic, climate or age relationship. HIV re-
lated BL mainly affects lymph nodes, and bone marrow 
is involved in only 30% of cases (9).
EBV appears in 97% of endemic LB, but only in 20-
30% of non endemic cases (4,8). In the case here re-
ported, there was no evidence of EBV.
Temporary or definitive teeth loss or displacement, gin-
gival expansion, numb chin, and tooth ache secondary 
to pulpal infiltration with tumour cells (what is charac-
teristic in this tumour)  are early signs of BL (1,9-11). Ra-
diologically, the tumour appears as a radiolucent lesion 
with early loss of the lamina dura around developing 
teeth (1,8,12). Symptoms due to the general affectation 
of the patient, or to compression of adjacent anatomical 
structures by the tumour, such as pharynx, trachea, su-
perior cava vein or central nervous system (CNS) may 
appear (3,4). Bone scintigraphy shows hypercaptation 
in early stages. Bone marrow biopsy, cytogenetic stud-
ies, and immunophenotypic analysis support definitive 
diagnosis of the disease. The classical histological pat-
tern is conformed by a thick and diffuse monoclonal 
proliferation of small dark cytoplasm noncleaved neo-
plastic cells with some interspersed clear macrophagic 
cells (1-4). The high mitotic index observed in the slices 
indicates BL´s high proliferative activity whose tumoral 
duplication time is approximately as high as 26 hours 
(4,8). In both  endemic and sporadic clinical subtypes, 
t(8,14) translocation appears (1-3, 8-10) with differences 
at the molecular level with regard to the sites of chro-
mosomal rupture.
Intensive chemotherapy has allowed a survival rate to 
five years for early stages up to 90-100% and a larger 
disease free period, with less long term toxicity. Local 
complications include caries, mucositis, gingivitis, her-
petic stomatitis and candidiasis (13,14). New chemother-
apeutic agents such as daunorrubicine, arabinoside-C, 
tioguanide and hidroxiurea have been added to the clas-
sical treatment scheme COMP. When involvement of 
CNS is suspected phrophylaxis by means of intrathecal 
instillation with metrotrexate or citarabine is recom-
mended. Bone marrow transplantation is an alternative 
in cases of persistence in spite of intensive treatment. 
Monoclonal antibodies constitute a future therapeutic 
strategy  in the treatment of these tumours (3). Due to 
its rapid spread, surgical resection its limited to those 
cases with obstructive symptomatology compromising 
survival (2). Cranio-spinal irradiation may be effective 
as prophylaxis of spread to the CNS and as a treatment 
alternative to achieve immediate relief of symptoms de-
rived from compression to CNS structures. The role of 
radiotherapy as a coadjuvant treatment for the disease 
affecting the jaws is still to be determined. According 
to literature, a dose of 7-30 Gy is recommended (3). In 
the case here reported, the total dose of radiation was 
26 Gy.
As in the case here shown (Fig. 3), children which have 
received radiation may develop noticeable impairment 
Table 1. Differential characteristics of BL subtypes. BL: Burkitt s´ lymphoma; t: translocation; HIV: human immunodeficiency virus.
BL clinical subtype Endemic Sporadic HIV related
Epidemiology Central Africa and New Guinea Rest of the world: USA, Europe
Rest of the world: USA, 
Europe
Incidence 10 cases/105 1-3 cases/105 6 /103 AIDS cases
Genetics t(8,14) breaking point over c-myc t(8,14) breaking point in c-myc
t(8,14) breaking point in 
c-myc
Location Jaws and facial bones in children
Abdominal mass in older chil-
dren and adults Lymphatic organ in adults
Survival with treatment Good (90%) Good (90%) Lower (40%)
Serology for EBV 97% 20-30% 20-30%
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in the development of dental and maxillofacial struc-
tures, such as blunt roots, incomplete calcification, fa-
cial asymmetric growth and occlusal changes (15,16). 
Specific periodontal problems may also appear showing 
a decrease of the osteoblastic and osteoclastic activity in 
the alveolar bone, almost complete lack of osteocytes, 
and degeneration of fat marrow. Odontoblastic activity 
stops in developing teeth, with the result of agenesias 
and microdontias (15,17).
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